Implementing <scp><i>DPYD</i></scp> genotyping to predict chemotherapy toxicity in Australia: a feasibility study
DPYD genotyping is feasible for improving precision-oncology for patients requiring FP chemotherapies. A TAT of 7 days is acceptable by both stakeholder respondents and national oncology clinician groups. This pilot study, although small, informs a large national project evaluating prospective DPYD genotyping and its impact on FP tolerability, patient safety and cost-effectiveness in Australia.
Authors
- Rodney J. Scott
- Stephen P. Ackland (ORCID: https://orcid.org/0000-0001-5303-0017)
- Cassandra White (ORCID: https://orcid.org/0000-0001-5268-2793)
- David Mossman
- Andrew Ziolkowski
- Christine Paul (ORCID: https://orcid.org/0000-0002-0504-5246)
- Esther Liet
- Dilshan Kalpage
Institutions
- John Hunter Hospital (AU)
- Hunter Medical Research Institute (AU)
- University of Newcastle Australia (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1111/imj.16576
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Newcastle Australia